ArticleMicroorganisms2022
Clinical Effects of
Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Effectiveness of probiotics on COVID-19 prevention and treatment against mild COVID-19 in outpatient care: A systematic review.Nutrition and health · 2026Pooled it
- The effect of probiotics on the risk of mortality in patients with COVID-19: systematic review and meta-analysis of randomized trials.Inflammopharmacology · 2023Pooled it
- Probiotics for the prevention and treatment of COVID-19: a rapid systematic review and meta-analysis.Frontiers in nutrition · 2023Pooled it
- Study to evaluate the safety and tolerability ofFrontiers in nutrition · 2025Trial
- Use ofFrontiers in immunology · 2023Trial
- Attenuated efficacy of Streptococcus salivarius K12 against Mycoplasma pneumoniae infection in mice.BMC microbiology · 2026Article
- Metagenomic next-generation sequencing reveals microbial community characteristics during acute exacerbations of interstitial pneumonia and their associations with clinical phenotypes.Frontiers in cellular and infection microbiology · 2026Article
- Article
- The Role of Probiotics and Their Postbiotic Metabolites in Post-COVID-19 Syndrome.Molecules (Basel, Switzerland) · 2025Review
- Position statement of the Microbiota International Clinical Society.Frontiers in microbiomes · 2025Article
- Potential pharmacological effect of Quercetin Phytosome™ in the management of hyperuricemia: results from real-life clinical studies.Frontiers in nutrition · 2025Article
- From periodontal infection to oral-systemic dysbiosis: re-framing the oral microbiome's role in systemic health and the prophylactic potential ofFrontiers in microbiology · 2025Article
- [Protective effect ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Assessment of Perceived Effort Through On-Field Hydration Monitoring: A Case Analysis.Life (Basel, Switzerland) · 2024Article
- Efficacy ofMicroorganisms · 2024Article
- The Role of Short-Chain Fatty Acids, Particularly Butyrate, in Oncological Immunotherapy with Checkpoint Inhibitors: The Effectiveness of Complementary Treatment withMicroorganisms · 2024Review
- Sports-Related Gastrointestinal Disorders: From the Microbiota to the Possible Role of Nutraceuticals, a Narrative Analysis.Microorganisms · 2024Review
- Alterations in microbiota of patients with COVID-19: implications for therapeutic interventions.MedComm · 2024Review
- Expert consensus on the use of oropharyngeal probiotic Bactoblis in respiratory tract infection and otitis media: available clinical evidence and recommendations for future research.Frontiers in pediatrics · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anatomical and physiological considerations indicate that the oral cavity is a primary source of the lung microbiota community, and recent studies have shown that the microbiota in the lungs contributes to immunological homeostasis, potentially altering the organ's susceptibility to viral infection, including SARS-CoV-2. It has been proposed that, in the case of viral infection, lung Gram-negative bacteria could promote the cytokine cascade with a better performance than a microbiota mainly constituted by Gram-positive bacteria. Recent observations also suggest that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.